Core Insights - Merus N.V. (MRUS) shares have increased by 29.9% over the past three months, driven by positive interim results from a phase II study of its bispecific antibody, petosemtamab (MCLA-158), in combination with Merck's Keytruda for treating PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) [1][4] Study Results - As of February 27, 2025, 45 patients were treated, with 43 deemed efficacy-evaluable, resulting in a confirmed overall response rate (ORR) of 63%, which included six complete responses and 21 partial responses [2] - The ORR varied with PD-L1 expression levels, showing a 73% ORR in patients with a combined positive score (CPS) greater than 20 and 47% in those with CPS 1–19 [2] - Median progression-free survival was reported at nine months, with an overall survival rate of 79% at 12 months [3] Safety Profile - The safety profile of the combination therapy was manageable, with no significant overlapping toxicities reported with Keytruda; treatment-related adverse events occurred in all patients, with infusion-related reactions observed in 38% [5][6] Future Prospects - The promising data suggests that the petosemtamab combination therapy could become a new standard of care for HNSCC, a cancer type with poor prognosis [6] - Merus is also conducting a registrational phase III study (LiGeR-HN1) for the combination therapy and another study (LiGeR-HN2) for petosemtamab monotherapy [7][8] Market Context - Merck's Keytruda, a leading anti-PD-1 therapy, generated $7.21 billion in sales in Q1 2025, reflecting a 6% year-over-year increase, and continues to expand into new indications and markets [8][10]

Investment Rating - The report does not explicitly provide an investment rating for the industry Core Insights - The Trump administration's recent tariff increases are expected to significantly impact consumer prices, similar to the effects observed during the 2018-2019 trade war [2][5] - Preliminary data indicates that the effective tariff rate has increased by approximately 7.2 percentage points (pp) as of May, with expectations of a total increase to about 14pp with additional sectoral tariffs [14][29] - The analysis suggests that foreign exporters have absorbed about 20% of the tariff costs, while the remaining costs are split between US businesses and consumers [29][34] Summary by Sections Tariff Implementation and Effects - Tariff hikes began in early February, with significant increases taking effect in April, leading to delayed impacts on consumer prices due to shipping and payment delays [2][8][10] - The effective tariff rate is estimated to have risen by 9pp, with customs revenue indicating a lower increase of 7.2pp due to various delays [14][18] Cost Absorption and Price Changes - Price data through May shows that a 1pp increase in product-level tariff rates has led to a 0.2% decline in import prices, primarily driven by China [21][27] - The share of tariff costs passed onto consumers increased from 0% in the first month to 10% after two months, and to 40% after three months [3][46] Core PCE Inflation Forecast - Tariffs have raised core PCE prices by approximately 6 basis points (bp) this year, suggesting that without tariffs, the current core PCE inflation rate of 2.7% would be 2.6% [52] - The report maintains an unchanged inflation forecast, expecting tariff effects to boost core PCE inflation by about 1pp this year, leading to a year-over-year rate of around 3.3% in December [53][58]

当前，全球医药健康产业进入创新浪潮奔涌、发展范式跃迁的关键时期，创新药研发范式加速迭代、 AI技术重塑研发链条、合成生物学不断突破产业化瓶颈。 中国市场医药健康产业也在变革中加速发展，尤其是创新药领域迎来"DeepSeek"时刻，实现从跟随者到 领跑者的产业跃迁。 北京昌平正致力于打造成为，汇聚全产业链资源的医药健康产业创新高地。据了解，近年来，昌平区聚 焦打造具有全球领先水平的"生命谷"，以生命科学园为核心，布局建设生命科学创新走廊，持续构 建"投资+临床+孵化+园区"医药健康产业生态圈，搭建各类共性技术与公共服务平台57个，形成了涵盖 基础研究到终端医疗的完整产业链。 过去三年，昌平全区医药健康产业收入年均增速9.3%，2024年达到1040亿元，同比增长14.3%。同时值 得注意的是，昌平持续引金融活水助力医药健康企业的创新发展。2024年3月，规模达200亿元的北京市 医药健康产业投资基金在昌平设立，该基金重点布局创新药、创新医疗（002173）器械等重点领域，由 顺禧管理公司联合康桥资本共同管理。 7月7日，在2025昌平医药健康金融投资创新论坛上，北京国有资本运营管理有限公司党委副书记，董 事、总 ...

The previously disclosed and now published RESILIENT data show that once-nightly TNX-102 SL achieved statistically significant improvement in the primary endpoint of reducing fibromyalgia pain versus placebo, and was generally well tolerated These results confirm findings from the previously published RELIEF phase 3 trial, which also demonstrated a statistically significant reduction in fibromyalgia pain FDA target PDUFA date for TNX-102 SL is August 15, 2025 and, if approved, would be the first new drug fo ...

"AI（人工智能）制药最大的优势是快，因为它加速了'发现—验证—重新优化'的循环。"微芯生物研发 总监潘德思在接受采访时如是说。 近期，AI制药因频繁的项目合作和投融资事件受到市场关注。证券时报记者从业内了解到，随着AI加 速向医药行业渗透，创新药研发迎来里程碑式进步，AI制药的成果多点开花。与此同时，AI制药面临 着商业化困境，解决还需时日。 AI制药领域大单频现 近期，AI制药领域的大额订单频现。6月11日，诺和诺德与AI制药公司Deep Apple Therapeutics达成8.12 亿美元合作；6月12日，礼来与Juvena Therapeutics（美国AI制药公司）签署超过6.5亿美元的协议；6月 13日，阿斯利康（AZ）与石药集团达成最高达53亿美元合作，利用石药集团的AI药物发现平台开发小 分子候选药物。6月23日，国内AI制药龙头企业晶泰控股与DoveTree LLC（美国医药界的传奇创业者及 投资人Gregory Verdine所设立的公司）签署数十亿美元管线授权合作意向书；同日，AI制药公司 Formation Bio宣布其子公司已将口服双重JAK/SYK抑制剂gusacitinib授 ...

Joe Rogan touts testosterone shots to his 20m listeners as a way to help men feel younger. Gym-bros and “biohackers” inject themselves with it on TikTok. Are they promoting something safe? https://t.co/byLysWpsLK ...

Between 2019 and 2024 prescriptions for testosterone in America jumped from 7.3m to 11m. What explains this health fad? https://t.co/R7qyOscWuS ...

katana sitting on 380M undistributed $KAT tokenscurrent yield sources:• dual $SUSHI/$KAT emissions live• jitoSOL/uSOL rewards active• morpho integration pulling depositstvl hit $430M with only 120M tokens deployedexpecting full distribution by month-end as sushi pools mature ...

Key Takeaways CHWY delivered a 6.2% adjusted EBITDA margin in Q1, increasing 50 basis points y/y. Stronger Autoship and ads contributed to a more profitable and balanced revenue mix. Management reiterated the 2025 view and confidence in reaching the 10% adjusted EBITDA margin objective.Chewy (CHWY) reported a 6.2% adjusted EBITDA margin in the first quarter of fiscal 2025, expanding 50 basis points year over year. Adjusted EBITDA rose 18.3% to $192.7 million from $162.9 million a year ago. These results h ...

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox TNX-801 confers durable protection after a single dose TNX-801 is well tolerated in immunocompromised animals, without evidence of spreading to blood or tissues even at high doses CHATHAM, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company with marketed products and a pipeline ...